Classical Hodgkin LymphomaSymptoms, Doctors, Treatments, Advances & More
Learn About Classical Hodgkin Lymphoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Emory Winship Cancer Institute
Kristie Blum is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. She has been practicing medicine for over 29 years. Dr. Blum is rated as an Elite provider by MediFind in the treatment of Classical Hodgkin Lymphoma. She is also highly rated in 21 other conditions, according to our data. Her clinical expertise encompasses Mantle Cell Lymphoma (MCL), Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Blum is board certified in American Board Of Internal Medicine, 2004.
Emory Winship Cancer Institute
Jonathon Cohen is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 19 years. Dr. Cohen is rated as an Elite provider by MediFind in the treatment of Classical Hodgkin Lymphoma. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Vitrectomy. Dr. Cohen is board certified in American Board Of Internal Medicine, 2014.
Cleveland Clinic Main Campus
Paolo Caimi is a Hematologist Oncology specialist and a Hematologist practicing medicine in Cleveland, Ohio. Dr. Caimi is rated as an Elite provider by MediFind in the treatment of Classical Hodgkin Lymphoma. He is also highly rated in 37 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Caimi is board certified in American Board Of Internal Medicine, 2011.
Summary: This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
Summary: This phase II study is designed to determine the clinical efficacy of PD-1 inhibitors, administered as maintenance therapy after autologous stem cell transplant (autoHCT), in patients with relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL)